Bristol Myers Reaches $239 Million Settlement Over Psoriasis, MS Drugs
Insurance Journal - Nov 07, 2025
Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia. A preliminary settlement of the 7-1/2-year-old class action was …...
Recommended Articles
Posted: Apr 02, 2026
Kalepa, headquartered in New York City, appointed Audrey Howell as head of product. Howell will lead...
Posted: Apr 02, 2026
A number of Baidu Inc.’s Apollo Go robotaxis suddenly stopped on the streets of China’s...
Posted: Apr 02, 2026
Perplexity AI Inc. was accused in a lawsuit of surreptitiously sharing the personal information of i...